Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy.
作者信息
Mehta Neesurg, Robbins Deborah A, Yiu Glenn
出版信息
Int Ophthalmol Clin. 2021 Jul 1;61(3):151-177. doi: 10.1097/IIO.0000000000000366.
Abstract
摘要
相似文献
1
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy.视网膜基因治疗中的眼部炎症及治疗突发不良事件
Int Ophthalmol Clin. 2021 Jul 1;61(3):151-177. doi: 10.1097/IIO.0000000000000366.
2
Hyperbaric oxygen therapy and the eye.高压氧疗法与眼睛
Undersea Hyperb Med. 2008 Sep-Oct;35(5):333-87.
3
[Homogenous color vision disorders, independent from vision acuity, in three siblings with macula degeneration].[三名患有黄斑变性的兄弟姐妹中存在与视力敏锐度无关的均匀性色觉障碍]
Albrecht Von Graefes Arch Ophthalmol. 1955;156(3):323-7.
4
Safety evaluation of "retina implant alpha IMS"--a prospective clinical trial.“视网膜植入物阿尔法 IMS”的安全性评估——一项前瞻性临床试验。
Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):381-7. doi: 10.1007/s00417-014-2797-x. Epub 2014 Sep 16.
5
The electrical phosphene threshold as a measure of retinal induction and visual organization.作为视网膜诱导和视觉组织测量指标的电刺激光幻视阈值。
J Exp Psychol. 1957 Jul;54(1):21-7. doi: 10.1037/h0049264.
6
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.眼部AAV2-RPE65在非人灵长类动物中的安全性，一种用于治疗莱伯先天性黑蒙失明的候选疗法。
Hum Gene Ther. 2006 Aug;17(8):845-58. doi: 10.1089/hum.2006.17.845.
7
Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis.玻璃体内基因治疗可维持 CLN2 神经元神经鞘脂褐质沉积症犬模型的视网膜功能。
Exp Eye Res. 2023 Jan;226:109344. doi: 10.1016/j.exer.2022.109344. Epub 2022 Dec 9.
8
Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity.鼻腔和鼻窦恶性肿瘤放射治疗的晚期视网膜并发症：照射剂量区域与严重程度之间的关系。
Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):599-605. doi: 10.1016/s0360-3016(99)00057-7.
9
The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review.基因治疗治疗单基因视网膜和视神经疾病的安全性和有效性：系统评价。
Genet Med. 2022 Mar;24(3):521-534. doi: 10.1016/j.gim.2021.10.013. Epub 2021 Nov 30.
10
Anomalous retinal correspondence and monolateral squint.异常视网膜对应与单侧斜视。
Ophthalmologica. 1967;153(3):179-83. doi: 10.1159/000305056.
引用本文的文献
1
Gene therapy for age-related macular degeneration: a promising frontier in vision preservation.年龄相关性黄斑变性的基因治疗：视力保护的一个有前景的前沿领域。
Cell Commun Signal. 2025 May 20;23(1):233. doi: 10.1186/s12964-025-02246-4.
2
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).2024年生物分析近期问题白皮书：超越ADA/NAb的免疫原性评估演变；规范的基因组/NGS检测；超敏反应；最小降噪；假阳性范围；现代化疫苗方法；NAb/TAb相关性——基因治疗、细胞治疗、疫苗分子检测和免疫原性的先进策略建议；生物治疗药物免疫原性评估与临床相关性——监管机构对生物治疗药物、基因、细胞和疫苗治疗的免疫原性/技术的意见）
Bioanalysis. 2025 Feb;17(3):105-149. doi: 10.1080/17576180.2024.2439229. Epub 2025 Jan 25.
3
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses.马玻璃体内注射AAV-eqIL-10后的眼毒性、分布及脱落情况
Mol Ther Methods Clin Dev. 2024 Oct 28;32(4):101360. doi: 10.1016/j.omtm.2024.101360. eCollection 2024 Dec 12.
4
Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies.眼部治疗的进展：新兴药物递送方法和制药技术综述
Pharmaceutics. 2024 Oct 12;16(10):1325. doi: 10.3390/pharmaceutics16101325.
5
Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions.眼科治疗药物传递的新进展：当前和未来方向的全面综述。
Surv Ophthalmol. 2024 Nov-Dec;69(6):967-983. doi: 10.1016/j.survophthal.2024.07.002. Epub 2024 Jul 8.
6
AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?腺相关病毒介导的青光眼和葡萄膜炎基因治疗：我们成功了吗？
Expert Rev Mol Med. 2024 Apr 15;26:e9. doi: 10.1017/erm.2024.4.
7
Role of FoxP3 Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy.FoxP3 调节性 T 细胞在调节腺相关病毒基因治疗中的免疫反应的作用。
Hum Gene Ther. 2024 Jul;35(13-14):439-450. doi: 10.1089/hum.2023.227. Epub 2024 Apr 11.
8
Immunology of Retinitis Pigmentosa and Gene Therapy-Associated Uveitis.色素性视网膜炎和基因治疗相关性葡萄膜炎的免疫学
Cold Spring Harb Perspect Med. 2024 Jan 2;14(1):a041305. doi: 10.1101/cshperspect.a041305.
9
The Degree of Adeno-Associated Virus-Induced Retinal Inflammation Varies Based on Serotype and Route of Delivery: Intravitreal, Subretinal, or Suprachoroidal.腺相关病毒诱导的视网膜炎症程度因血清型和给药途径而异：玻璃体内、视网膜下或脉络膜上。
Hum Gene Ther. 2023 Jun;34(11-12):530-539. doi: 10.1089/hum.2022.222. Epub 2023 Mar 28.
10
Ocular Gene Therapy: A Literature Review With Focus on Current Clinical Trials.眼部基因治疗：聚焦当前临床试验的文献综述
Cureus. 2022 Sep 24;14(9):e29533. doi: 10.7759/cureus.29533. eCollection 2022 Sep.
本文引用的文献
1
Targeting vascular endothelial growth factor using retinal gene therapy.利用视网膜基因疗法靶向血管内皮生长因子。
Ann Transl Med. 2021 Aug;9(15):1277. doi: 10.21037/atm-20-4417.
2
Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes.AAV8 经脉络膜下给药后非人灵长类动物眼内的宿主免疫反应。
Hum Gene Ther. 2021 Jul;32(13-14):682-693. doi: 10.1089/hum.2020.281. Epub 2021 Apr 8.
3
Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety.腺相关病毒载体介导的视网膜基因治疗的免疫反应 - 对治疗成功和安全性的影响。
Prog Retin Eye Res. 2021 Jul;83:100915. doi: 10.1016/j.preteyeres.2020.100915. Epub 2020 Oct 15.
4
Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review.遗传性视网膜疾病基因治疗试验中的治疗突发不良事件：一项叙述性综述。
Ophthalmol Ther. 2020 Dec;9(4):709-724. doi: 10.1007/s40123-020-00287-1. Epub 2020 Aug 1.
5
Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.眼基因治疗临床试验和转基因表达及生物活性测定中的重组腺相关病毒载体（rAAV）-载体元件。
Int J Mol Sci. 2020 Jun 12;21(12):4197. doi: 10.3390/ijms21124197.
6
Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial.针对无色素性视锥细胞营养不良的视网膜下基因治疗的安全性和视觉效果：一项非随机对照试验。
JAMA Ophthalmol. 2020 Jun 1;138(6):643-651. doi: 10.1001/jamaophthalmol.2020.1032.
7
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial.脉络膜上腔注射 CLS-TA 治疗非感染性葡萄膜炎继发黄斑水肿的疗效和安全性：3 期随机试验。
Ophthalmology. 2020 Jul;127(7):948-955. doi: 10.1016/j.ophtha.2020.01.006. Epub 2020 Jan 10.
8
The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis.人 RPE65 相关莱伯先天性黑矇基因治疗对视功能的影响：系统评价和荟萃分析。
Orphanet J Rare Dis. 2020 Feb 14;15(1):49. doi: 10.1186/s13023-020-1304-1.
9
Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates.使用经巩膜微针进行脉络膜上腔和视网膜下注射腺相关病毒用于非人灵长类动物的视网膜基因递送
Mol Ther Methods Clin Dev. 2020 Jan 21;16:179-191. doi: 10.1016/j.omtm.2020.01.002. eCollection 2020 Mar 13.
10
Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study.用于年龄相关性黄斑变性的脉络膜下注射 palucorcel 的安全性和疗效：2b 期研究。
Ophthalmol Retina. 2020 Apr;4(4):384-393. doi: 10.1016/j.oret.2019.11.011. Epub 2019 Nov 19.
Zotero 插件